IJCM  Vol.6 No.9 , September 2015
Hemoglobin Level Stability after a Switch from Darbepoetin Alfa to Epoetin Beta Pegol for the Treatment of Renal Anemia in Hemodialysis Patients
ABSTRACT
Background: New erythropoiesis-stimulating agents (ESAs) with a longer half-life have been developed for the treatment of anemia as a complication of patients with end-stage renal disease. Objectives: The objective of the present study was to assess the hemoglobin (Hb) stability of a Japanese cohort of hemodialysis (HD) patients who were simultaneously switched from darbepoetin alfa (DA) to epoetin beta pegol (CERA). Methods: This was an observational, prospective study of HD patients 20 years of age or more who were switched from intravenous (IV) DA to IV CERA and continued on HD for at least 3 months. The dose was adjusted to maintain the Hb level to within 1.0 g/dl of the baseline value. Results: A total of 68 HD patients (75.0% male, median age 63.0 years) were enrolled. The patients’ mean Hb levels were 10.8 ± (0.6) g/dl at Month 0, 10.9 ± 0.7 at Month 1, 10.8 ± 0.7 at Month 2, and 10.9 ± 0.8 at Month 3, and the differences from the level at Month 0 were not significant. After the switch, the ESA dose decreased significantly (P < 0.0001) from an annual mean DA dose of 549.0 ± 246.6 IU/kg/month to a mean CERA dose at Month of 3 491.0 ± 291.7 IU/kg/month. The ESA resistance index (ERI) decreased from 51.7 ± 24.4 IU/kg/ month/g/dl on DA at Month 0 to 46.4 ± 29.3 on CERA at 3 Month 3 (P < 0.0001). Conclusion: Switching from DA to CERA was associated with approximate 89% reduction of the required dose in Japanese HD patients being treated with an ESA and showed a favorable impact on the treatment of renal anemia, including the need for less frequent injections and a reduction of the ESA dose.

Cite this paper
Takahashi, S. , Tanaka, Y. , Takano, M. , Suzuki, K. , Ueda, M. , Shimamoto, Y. and Nitta, K. (2015) Hemoglobin Level Stability after a Switch from Darbepoetin Alfa to Epoetin Beta Pegol for the Treatment of Renal Anemia in Hemodialysis Patients. International Journal of Clinical Medicine, 6, 652-660. doi: 10.4236/ijcm.2015.69087.
References
[1]   Eschbach, J.W. and Adamson, J.W. (1988) Recombinant Human Erythropoietin: Implications for Nephrology. American Journal of Kidney Diseases, 11, 203-209.
http://dx.doi.org/10.1016/S0272-6386(88)80150-1

[2]   Macdougall, I.C. (2002) Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations. Nephrology Dialysis Transplantation, 17, 66-70.
http://dx.doi.org/10.1093/ndt/17.suppl_5.66

[3]   Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.U., et al. (2004) Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrology Dialysis Transplantation, 19, ii1-ii47.

[4]   Fishbane, S. (2010) The Role of Erythropoiesis-Stimulating Agents in the Treatment of Anemia. American Journal of Managed Care, 16, S67-S73.

[5]   Halstenson, C.E., Macres, M., Katz, S.A., Schnieders, J.R., Watanabe, M., Sobota, J.T. and Abraham, P.A. (1991) Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Beta. Clinical Pharmacology and Therapeutics, 50, 702-712.
http://dx.doi.org/10.1038/clpt.1991.210

[6]   Macdougall, I.C. (2002) Dalbepoetin Alfa: A New Therapeutic Agent for Renal Anemia. Kidney International Suppl., 61, S55-S61.
http://dx.doi.org/10.1046/j.1523-1755.61.s80.11.x

[7]   Hudson, J.Q. and Sameri, R.M. (2002) Dalbepoetin Alfa, a New Therapy for the Management of Anemia of Chronic Kidney Disease. Pharmacotherapy, 22, 141S-149S.
http://dx.doi.org/10.1592/phco.22.14.141S.33397

[8]   Aljama, P., Bommer, J., Canaud, B., Carrera, F., Eckardt, K.U., Horl, W.H., et al. (2001) Practical Guidelines for the Use of HESP in Treating Renal Anaemia. Nephrology Dialysis Transplantation, 16, 22-28.
http://dx.doi.org/10.1093/ndt/16.suppl_3.22

[9]   Macdougall, I.C., Gray, S.J., Elston, O., Breen, C., Jenkins, B., Browne, J. and Egrie, J. (1999) Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients. Journal of American Society of Nephrology, 10, 2392-2395.

[10]   Locatelli, F. and Reigner, B. (2007) C.E.R.A.: Pharmacodynamics, Pharmacokinetics and Efficacy in Patients with Chronic Kidney Disease. Expert opinion on Investigational Drugs, 16, 1649-1661.
http://dx.doi.org/10.1517/13543784.16.10.1649

[11]   Takahashi, S., Suzuki, K., Kojima, F., Tanaka, Y. and Nitta, K. (2015) Geriatric Nutritional Risk Index as a Simple Predictor of Mortality in Maintenance Hemodialysis Patients: A Single Center Study. International Journal of Clinical Medicine, 6, 354-362.
http://dx.doi.org/10.4236/ijcm.2015.65046

[12]   Tsubakihara, Y., Nishi, S., Akiba, T., Hirakata, H., Iseki, K., Kubota, M., et al. (2010) 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Therapeutic Apheresis and Dialysis, 14, 240-275.
http://dx.doi.org/10.1111/j.1744-9987.2010.00836.x

[13]   Okazaki, M., Komatsu, M., Kawaguchi, H., Tsuchiya, K. and Nitta, K. (2014) Erythropoietin Resistance Index and the All-Cause Mortality of Chronic Hemodialysis Patients. Blood Purification, 37, 106-112.
http://dx.doi.org/10.1159/000358215

[14]   Ogawa, T., Shimizu, H., Kyono, A., Sato, M., Yamashita, T., Otsuka, K. and Nitta, K. (2014) Relationship between Responsiveness to Erythropoietin-Stimulating Agent and Long-Term Outcomes in Chronic Hemodialysis Patients: A Single Center Cohort Study. International Urology and Nephrology, 46, 151-159.
http://dx.doi.org/10.1007/s11255-013-0494-z

[15]   Hirai, T., Nishizawa, Y., Nakazono, H., Asai, M., Yamashita, H., Sasaki, A., et al. (2013) Hemoglobin Maintenance and Dosing Strategies Using Intravenous Continuous Erythropoietin Receptor Activator in Japanese Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 17, 498-503.
http://dx.doi.org/10.1111/1744-9987.12013

[16]   Fishbane, S. and Berns, J.S. (2007) Evidence and Implications of Haemoglobin Cycling in Anemia Management. Nephrology Dialysis Transplantation, 22, 2129-2132.
http://dx.doi.org/10.1093/ndt/gfm384

[17]   Besarab, A., Salifu, M.O., Lunde, N.M., Bansal, V., Fishbane, S., Dougherty, F.C., et al. (2007) Efficacy and Tolerability of Continuous Erythropoietin Receptor Activator: A 19-Week, Phase II, Multicenter, Randomized, Open-Label, Dose-Finding Study with a 12-Month Extension Phase in Patients with Chronic Renal Disease. Clinical Therapy, 29, 626-639.
http://dx.doi.org/10.1016/j.clinthera.2007.04.014

[18]   Morikami, Y., Fujimori, A., Okada, S., Kumei, M., Mizobuchi, N. and Sakai, M. (2014) Comparison of 2-Week versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 18, 414-420.
http://dx.doi.org/10.1111/1744-9987.12164

 
 
Top